Citation Impact
Citing Papers
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Estimating the mean and variance from the median, range, and the size of a sample
2005 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome
2007
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas
2006
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
2009
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
2010
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
2002
HER-2/neu Assessment in Breast Cancer Using the Original FDA and New ASCO/CAP Guideline Recommendations
2008
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study
2014
Quantitative PCR and HER2 Testing in Breast Cancer
2008
Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
2008
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Overexpression of Id‐1 is associated with poor clinical outcome in node negative breast cancer
2003
Comparison of Quantitative Immunofluorescence With Conventional Methods for HER2/ neu Testing With Respect to Response to Trastuzumab Therapy in Metastatic Breast Cancer
2008
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
2010
Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients
2003
Pathogenesis and treatment of anaemia of chronic disease
2002
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Breast cancer
2016 Standout
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
2008
Racial differences in the expression of cell cycle–regulatory proteins in breast carcinoma
2004
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
2003 Standout
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
2004 Standout
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
2011
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Dermatologist-level classification of skin cancer with deep neural networks
2017 StandoutNature
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer
2010
Immunology and immunotherapy of colorectal cancer
2003
Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
2005
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
1997
Global functional profiling of gene expression☆☆This work was funded in part by a Sun Microsystems grant awarded to S.D., NIH Grant HD36512 to S.A.K., a Wayne State University SOM Dean’s Post-Doctoral Fellowship, and an NICHD Contraception and Infertility Loan to G.C.O. Support from the WSU MCBI mode is gratefully appreciated.
2003
p21 in cancer: intricate networks and multiple activities
2009 Standout
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
2016
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
p53 in health and disease
2007 Standout
Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations
2002
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
1998
Emerging Biological Principles of Metastasis
2017 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
p53 mutation heterogeneity in cancer
2005
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
2005
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Late Recurrences in Early Breast Cancer: For Whom and How Long Is Endocrine Therapy Beneficial?
2014
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer
2006
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Erythropoietin for patients with malignant disease
2004
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
2014
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
2015
Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
2010
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Anemia of Chronic Disease
2005 Standout
Breast cancer metastasis: markers and models
2005 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Erythropoietin, iron, and erythropoiesis
2000
Dissecting racial bias in an algorithm used to manage the health of populations
2019 StandoutScience
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
2001
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
2006
Breast Cancer Treatment
2019 Standout
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia.
1997
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role ofPGC1andNRF1
2003 Standout
Immunization With Mutantp53- andK-ras–Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome
2005
Erythropoietin, iron, and erythropoiesis.
2000
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Iron-Deficiency Anemia
2015 Standout
Erythropoietin, iron, and erythropoiesis
2000
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
2000 Standout
Chromogenic In Situ Hybridization to Detect HER-2/neu Gene Amplification in Histological and ThinPrep®-Processed Breast Cancer Fine-Needle Aspirates: A Sensitive and Practical Method in the Trastuzumab Era
2006
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Computer Aided Diagnostic Support System for Skin Cancer: A Review of Techniques and Algorithms
2013
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Standout
Works of H. Samonigg being referenced
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.
2001
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
2007
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor
1998
In vivoconfocal laser scanning microscopy in the diagnosis of melanocytic skin tumours
2009
Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node–Positive Breast Cancer
1999
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
1999
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer
1995
Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotype antibody
1992
Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients
2013
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
2013
Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
2007
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients
2013
4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)
2009
P81 Benefits of switching postmenopausal women withhormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial
2005
A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer.
1999
Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)
2005
Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments]
1994
Prediction of response to erythropoietin treatment in chronic anemia of cancer [see comments]
1994
Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5
1999
6 vs. 3 cycles of epirubicin/docetaxel + G-CSF in operable breast cancer: results of ABCSG-14
2004